Physician profile
William E Pullano
NPI 1437175775
$675.01
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $66.34 · 2021: $51.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $141.93 | 2019 | |
| Ferring Pharmaceuticals INC. | $103.64 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.63 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $71.12 | 2019-2020 | |
| Qol Medical, LLC | $69.20 | 2019 | |
| Boston Scientific Corporation | $60.21 | 2019-2021 | |
| Horizon Therapeutics Plc | $53.64 | 2019-2021 | |
| Gilead Sciences, INC. | $24.65 | 2019 | |
| Endo Pharmaceuticals INC. | $21.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.92 | 2021 | |
| Romark Laboratories, Lc | $12.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pullano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.